Prothena Corporation plc - Ordinary Shares (PRTA) News
Filter PRTA News Items
PRTA News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
PRTA News Highlights
- For PRTA, its 30 day story count is now at 5.
- Over the past 13 days, the trend for PRTA's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- AC, ACIU and LGND are the most mentioned tickers in articles about PRTA.
Latest PRTA News From Around the Web
Below are the latest news stories about PROTHENA CORP PUBLIC LTD CO that investors may wish to consider to help them evaluate PRTA as an investment opportunity.
Prothena Corp PLC Chief Accounting Officer Sells Company SharesKarin Walker, Chief Accounting Officer of Prothena Corp PLC (NASDAQ:PRTA), sold 5,000 shares of the company on December 20, 2023, according to a recent SEC Filing. |
These 3 Biotech Stocks Have Strong Upside Potential, Says Deutsche BankBiotech is big business, no doubt about that. The healthcare sector takes up almost 1 in 5 dollars of the US gross domestic product, 18.3%, or approximately $13,000 per capita, according to data from the American Medical Association. The total sum is staggering – some $4.3 trillion. The US is the world leader in biomedical research, including innovation on new prescription drugs, medical devices, and other healthcare advances. The health sector R&D spend in the US comes to $250 billion annually. |
The Zacks Analyst Blog Highlights Biogen, Prothena, AC Immune's and VaxxinityBiogen, Prothena, AC Immune's and Vaxxinity are part of the Zacks top Analyst Blog. |
Alzheimer's Disease Space Evolves in 2023: Stocks in FocusThe approval of the breakthrough treatment Leqembi for Alzheimer's Disease has put this space in the spotlight. Companies like ACIU, VAXX and PRTA are in focus, given their experimental vaccines. |
Ligand (LGND) Up 12.4% Since Last Earnings Report: Can It Continue?Ligand (LGND) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. |
Prothena (NASDAQ:PRTA) shareholder returns have been strong, earning 207% in 5 yearsThe last three months have been tough on Prothena Corporation plc ( NASDAQ:PRTA ) shareholders, who have seen the share... |
Insider Sell Alert: Karin Walker of Prothena Corp PLC Cashes Out 5,000 SharesIn the realm of stock market movements, insider trading activity is often a significant indicator that investors keep an eye on to gauge the confidence level of a company's executives and directors in their own firm's prospects. |
FOCUS-Researchers return to Alzheimer's vaccines, buoyed by recent drug successBreakthrough Alzheimer’s treatments that remove toxic proteins from the brain have revived interest in vaccines to treat the memory-robbing disease, potentially offering a cheaper, easy-to-administer option for millions of people, according to interviews with 10 scientists and company executives. Clinical trials are underway or completed for at least seven Alzheimer’s vaccines designed to harness the immune system to rid the brain of the disease-related proteins beta amyloid or tau, a review of the U.S. government’s ClinicalTrials.gov database found. The renewed interest in Alzheimer's vaccines follows a promising first attempt more than 20 years ago that was abandoned after 6% of study volunteers developed life-threatening brain inflammation known as meningoencephalitis. |
Prothena (PRTA) Pipeline Shows Promise in a Tough AD MarketProthena (PRTA) makes good progress with its AD candidates. However, AD is a challenging space and the successful development of these candidates is crucial. |
Quest For Alzheimer's Cure: Big Biotech Breakthroughs, But The Race Is Just BeginningBiogen and Eisai scored key victories in the quest for an Alzheimer's cure. But the race is just getting started. |